EPIX options novel imaging agent to Schering
This article was originally published in Clinica
Executive Summary
German pharmaceuticals company Schering has exercised its option, under a previously-signed joint research agreement, with EPIX Pharmaceuticals to develop a novel imaging candidate indicated for diagnosing atherosclerosis and other vascular diseases.